The horizontal bar graph provides FDA actual and preliminary “on-time” performance on five actions related to original and resubmitted efficacy supplements to NDAs and BLAs. On-time goals range from 50 to 90 percent of actions. Performance results for FY 2004 and preliminary performance results for FY 2005 show that FDA is exceeding all five goals.